Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

Optimal empiric treatment for uncomplicated cellulitis

Clinical question: Is empiric MRSA coverage for nonpurulent cellulitis necessary?

Background: Most nonpurulent skin and soft tissue infections are caused by beta-hemolytic streptococci and methicillin-susceptible Staphylococcus aureus. However, there is a growing incidence of community-acquired methicillin-resistant S. aureus infections. The authors of this study attempted to answer whether adding empiric methicillin-resistant S. aureus coverage reduces the risk of treatment failure.

Dr. Emily Ramee, a hospitalist at Ochsner Health System, New Orleans

Dr. Emily Ramee

Study design: Multicenter, double-blind, randomized superiority trial.

Setting: Five emergency departments in the United States.

Synopsis: The authors of this study randomized 500 patients with cellulitis without purulent drainage or evidence of abscess as confirmed by sonography to receive a 7-day course of either cephalexin with placebo or cephalexin plus trimethoprim­sulfamethoxazole. When analyzing those patients who took most of the prescribed pills (greater than 75% of doses) according to treatment protocol, there was no significant difference in clinical cure rate between the two arms of the study, reaffirming current guidelines that advocate against empiric methicillin-resistant S. aureus coverage for uncomplicated cellulitis.

When the authors analyzed the result of their data with the assumption that patients who were lost to follow-up had treatment failure, there was a trend favoring the addition of trimethoprim-sulfamethoxazole with cephalexin over monotherapy with cephalexin (P = .07). Although the authors concluded that this finding may warrant further investigation, this was essentially a negative study.

Bottom line: Empirically adding community­-acquired methicillin-resistant S. aureus coverage with trimethoprim-sulfamethoxazole to uncomplicated cellulitis did not statistically improve a clinical cure, compared with empiric treatment with monotherapy with cephalexin.

Citation: Moran GJ, Krishnadasan A, Mower WR, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs. cephalexin alone on clinical cure of uncomplicated cellulitis. JAMA. 2017;317(20):2088-96.

Dr. Ramee is a hospitalist at Ochsner Health System, New Orleans.

  • 1

    Optimal empiric treatment for uncomplicated cellulitis

    October 6, 2017

  • 1

    Rectal temps in the nursery

    October 5, 2017

  • 1

    SHM suggests tweaks to CMS QPP proposal

    October 5, 2017

  • Here’s what’s trending at SHM – Oct. 2017

    October 5, 2017

  • 1

    Oral anticoagulation ‘reasonable’ in advanced kidney disease with A-fib

    October 5, 2017

  • 1

    Use of BZD and sedative-hypnotics among hospitalized elderly

    October 4, 2017

  • 1

    LVAD use soars in elderly Americans

    October 3, 2017

  • 1

    Sepsis time to treatment

    October 3, 2017

  • Upfront preparation key to QI projects

    October 2, 2017

  • Dabigatran, rivaroxaban linked to slight increase in GI bleeding risk

    October 2, 2017

1 … 443 444 445 446 447 … 975
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences